COMPLERA
Peakemtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate
NDAORALTABLETPriority Review
Approved
Aug 2011
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
7/8 — Comprehensive
Priority Review
COMPLERA (emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate) by Gilead Sciences is nucleoside reverse transcriptase inhibitors [moa]. Approved for human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor [epc]. First approved in 2011.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMPLERA is a fixed-dose combination tablet containing emtricitabine, rilpivirine, and tenofovir disoproxil fumarate for the treatment of HIV-1 infection. It works by inhibiting reverse transcriptase, a key enzyme in HIV replication, blocking the virus from converting its RNA into DNA. The drug is indicated for treatment-naïve and treatment-experienced HIV patients as part of antiretroviral therapy.
$26MPart D
PeakDeclining
6.4 years to LOECOMPLERA is a mature, declining product facing significant competitive pressure from next-generation fixed-dose combinations; commercial teams are consolidating and transitioning focus to newer assets.
Mechanism of Action
Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera
Started Oct 2012
33 enrolled
HIV-1 Infection
Career Relevance
COMPLERA roles are declining in headcount and strategic importance as Gilead transitions portfolio focus to BIKTARVY and next-generation regimens. Joining a COMPLERA team signals a mature-phase assignment focused on margin protection and transition planning rather than growth or innovation.
Brand Manager (Legacy Product)
Worked on COMPLERA at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.